ADRB1 and prostate carcinoma: Interestingly, although prostate cancer has the highest ADRB1 and ADRB2 expression of the malignancies studied in this meta-analysis [108], beta blockade in prostate cancer was not associated with CSS or OS improvement in this analysis.